> Details

Botta, Cirino; Agostino, Rita Maria; Dattola, Vincenzo; Cianci, Vittoria; Calandruccio, Natale Daniele; Bianco, Giovanna; Mafodda, Antonino; Maisano, Roberto; Iuliano, Eleonora; Orizzonte, Giovanna; Mazzacuva, Domenico; Falzea, Antonia Consuelo; Saladino, Rita Emilena; Giannicola, Rocco; Restifo, Giorgio; Aguglia, Umberto; Caraglia, Michele; Correale, Pierpaolo

Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune–Biological Evaluation and Case Report
  • Contributor: Botta, Cirino; Agostino, Rita Maria; Dattola, Vincenzo; Cianci, Vittoria; Calandruccio, Natale Daniele; Bianco, Giovanna; Mafodda, Antonino; Maisano, Roberto; Iuliano, Eleonora; Orizzonte, Giovanna; Mazzacuva, Domenico; Falzea, Antonia Consuelo; Saladino, Rita Emilena; Giannicola, Rocco; Restifo, Giorgio; Aguglia, Umberto; Caraglia, Michele; Correale, Pierpaolo
  • imprint: MDPI AG, 2021
  • Published in: International Journal of Molecular Sciences
  • Language: English
  • DOI: 10.3390/ijms22126246
  • ISSN: 1422-0067
  • Keywords: Inorganic Chemistry ; Organic Chemistry ; Physical and Theoretical Chemistry ; Computer Science Applications ; Spectroscopy ; Molecular Biology ; General Medicine ; Catalysis
  • Origination:
  • Footnote:
  • Description: <jats:p>Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a pyridostigmine and steroids-based therapy. This is the first report of concurrent M and MLS appearance in cancer patients receiving pembrolizumab. More efforts are needed to define early the risk and the clinical meaning of irAEs in this setting.</jats:p>
  • Access State: Open Access